for people ages 25-65 (full criteria)
healthy people welcome
at San Francisco, California
study started
estimated completion
Suneil Koliwad



Obesity affects over one third of US adults (>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time.

Official Title

Development of a Multi-Ethnic, Multimodal Obesity Cohort


The Inflammation, Diabetes, Ethnicity and Obesity (IDEO) cohort is recruiting 145 lean and obese individuals from three ethnicities, covering a spectrum of obesity and T2DM risk. Specifically, the cohort will include: 1) 45 obese subjects, including individuals each from three ethnic groups; Caucasian, Hispanic/Latino, and Chinese; 2) 45 subjects who are slated to undergo any type of bariatric surgery for obesity (20 individuals each from the three ethnic groups above); and 3) 55 lean controls, including individuals from each ethnicity.


Obesity Diabetes Mellitus ethnicity inflammation


You can join if…

Open to people ages 25-65

  • Subjects defined (lean and obese) from three defined ethnic groups; Caucasian, Hispanic/Latino, and Chinese.
  • Subjects will be between the ages of 25-65 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery.
  • BMI criteria for both surgical and nonsurgical obese patients and lean "controls" are as follows: Obese patients: BMI > 30 with standard comorbidities. For Chinese individual BMI cutoff for obesity is >27. Lean controls: BMI < 30 but BMI >18.5
  • Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.

You CAN'T join if...

  • Subjects with chronic kidney disease (> stage 3), chronic infections, autoimmune diseases.
  • Subjects with symptomatic heart failure or CAD, cirrhosis or liver failure.
  • Tobacco abuse
  • Subjects on glucocorticoids, immunosuppressants [ tacrolimus, cellcept] and PPAR-gamma agonist will be excluded from the study.


  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist

  • Suneil Koliwad
    Dr. Suneil Koliwad is an Endocrinologist and an Expert in Diabetes, Obesity, and Metabolism. His lab focuses on the intersection of nutrition, inflammation, and metabolic tissue function in the context of normal physiology, and diseases such as obesity, diabetes, fatty liver disease, and in the course of aging.


accepting new patients
Start Date
Completion Date
University of California, San Francisco
Related Info
Study Type
Last Updated